Bimzelx on SilverScript Choice (S5601-014)
bimekizumab
Covered, with prior authorization required.
Tier 5 (specialty tier). Quantity limit of 4 per 28 days.
$8,217.12
Patient pays / month, after deductible
$8,678.37
Patient pays / month, before the $615.00 deductible
Not offered
Patient pays / 90 days by mail
$0
After the yearly $2,100.00 out-of-pocket cap
BIMZELX 160 mg/mL Injection, Solution at a preferred retail pharmacy, from the plan's negotiated price of $32,868.49 for a month. Other covered strengths are listed below.
Prior authRequired on all 4 covered forms· The plan decides within 72 hours, or 24 if expedited· If denied, the prescriber can ask the plan to reconsider (an appeal)
All 4 covered strengths and forms
| Form | Tier | Patient pays / month | Limits |
|---|---|---|---|
| BIMZELX 160 mg/mL Injection, Solution | 5 | $8,711.21 | PA · 4 per 28 days |
| BIMZELX 160 mg/mL Injection, Solution | 5 | $8,217.12 | PA · 4 per 28 days |
| BIMZELX 320 mg/2mL Injection, Solution | 5 | $8,711.20 | PA · 4 per 28 days |
| BIMZELX 320 mg/2mL Injection, Solution | 5 | $8,711.20 | PA · 4 per 28 days |
Other IL-17 and IL-23 biologics on this plan
Verify with the plan before prescribing or filling. Member services: (866)235-5660. Data from the CMS 2026 Part D formulary and pricing files. Full plan details
Plan ID s5601-014